Terapia zatrucia zelazem

• Autorzy: Mendel M , Wiechetek M.

Warianty tytułu

EN

Therapy of iron poisoning

• Języki publikacji: PL

Abstrakty

EN

The therapy of iron poisoning requires different kinds of treatment. Gastric lavages and chelation therapy are routinely recommended in the management of the poisoned patient. It is always the best to use selective chelators that bind the excess iron in tissues. The most popular chelator is deferoxamine (DFO). It is used in parenteral therapy and brings relatively good results. Unfortunately, therapy with DFO also causes many adverse effects. Thus, many research institutes have concentrated on inventing new chelator-drugs. Consequently, there are currently some new medicines which give hope for better therapy of iron intoxication, e.g. NaHBED, ICL670. Besides specific treatment, it is always important to introduce a supportive therapy that corresponds to current symptoms.

Słowa kluczowe

PL

deferoksamina; zelazo; zatrucia; zwiazki chelatujace; leczenie; odtrutki

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 03
• Opis fizyczny: s.266-269,bibliogr.

Twórcy

autor

Mendel M

• Szkola Glowna Gospodarstwa Wiejskiego, ul.Ciszewskiego 8, 02-786 Warszawa

autor

Wiechetek M.

Bibliografia

• 1. Albertsen J. C.: Metals and Minerals - Iron, [w:] Konnie H. Plumlee (red.): Clinical Veterinary Toxicology. Mosby St. Louis 2004, 202-204.
• 2. Banner W., Woolf A. D.: Deferoksamine, [w:] Evaluation Antidotes for Poisoning by Metals and Metaloids. International Programe on Chemical Safety Evaluation (WHO/ILO/UNEP), Publication of WHO, Geneva, Switzerland 2004, 1-30.
• 3. Bąkała A., Wiechetek M.: Ograniczanie wchłaniania trucizn z przewodu pokarmowego u psów i kotów. Życie Wet. 2003, 78, 450-454.
• 4. Bergeron R. J., Wiegand J., Brittenham G. M.: HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatmant of chronic iron overload and acute iron poisoning. Blood 2002, 99, 3019-3026.
• 5. Beutler E., Hoffbrand A. V., Cook J. D.: Iron deficiency and overload, [w:] Hematology. American Society of Hematology, Education Program Book, Washington, USA 2003, 40-81.
• 6. Brittenham G. M.: Iron chelators and iron toxicity. Alcohol 2003, 30, 151-158.
• 7. Campbell A., Chapman M.: Iron and iron sats, [w:] Handbook of Poisoning in Dogs and Cats. Blackwell Science Ltd, Oxford 2000, 163-166.
• 8. Cappellini M. D.: Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best Pract. Res. Clin. Haematol. 2005, 18, 289-298.
• 9. Gfeller R. W., Messonnier S. P.: Iron, [w:] Handbook of Small Animal Toxicology and Poisonings. Mosby, St. Louis 2004, 202-204.
• 10. Gwaltney-Brant S. M., Rumbeiha W. K.: Newer antidotal therapies. Vet. Clin. Small Anim. 2002, 32, 323-329.
• 11. Hall J. O.: Iron, [w:] Peterson M. E., Talcott P. A. (red.): Small Animal Toxicology. Saunders W. B. Company Philadelphia, USA 2001, 524-530.
• 12. Kalinowski D. S., Richardson Des. R.: The evolution of iron chelators for thr treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583.
• 13. Kushner J. P., Porter J. P., Olivieri N. F.: Secondary iron overload, [w:] Hematology. American Society of Hematology, Education Program Book, Washington, USA 2001, 47-61.
• 14. Manoguerra A. S., Erdman A. R., Booze L. L., Christianson G., Wax P. M., Scharman E. J., Woolf A. D., Chyka P. A., Keyes D. C., Olson K .R., Caravati E. M., Troutman W. G.: Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol. 2005, 43, 553-570.
• 15. Mourad F. H., Hoffbrand A. V., Sheikh-Taha M., Koussa S.: Comparison between deferrioxamine and combined theraphy with deferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 2003, 121, 187-189.
• 16. Olivier N. F., Brittenham G. M.: Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89, 739-761.
• 17. Osweiler G. D.: Iron toxicosis, [w:] Osweiler G. D. (red.): Toxicology. The national veterinary medical series for independent study. Williams&Wilkins, Providence Road Media, USA 1996, 188-191.
• 18. Plumb D. C.: Drug monographs - deferoxamine, [w:] Veterinary Drug Handbook, Iowa State Press, Blackwell Publishing Company, USA 2002, 232-233.
• 19. Plumb D. C.: Drug monographs - edetate calcium disioium (calcium EDTA), [w:] Veterinary Drug Handbook. Iowa State Press, Blackwell Publishing Company, USA 2002, 304-305.
• 20. Richardson D. R., Milnes K.: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997, 89, 3025-3038.
• 21. Ruhr L. P. Nicholson S. S., Confer A. W., Blakewood N. W.: Acute intoxication from a hematinic in calves. J. Am. Vet. Med. Assoc. 1983, 182, 616-618.
• 22. Schubert S., Autenrieth I. B.: Conjugation of Hydroxyethyl Starch to Desferroxamine (DFO) Modulates the Dual Role of DFO in Yersinia enterocolitica Infection, Clinical and Diagnostic Laboratory Immunology. Clin. Diagn. Lab. Immunol. 2000, 7, 457-462.
• 23. Smith J. P.: Iron metabolism and its disordes, [w:] Kaneko J. J., Harvey J. W., Bruss M. L. (red.): Clinical Biochemistry of Domestic Animals. Academic Press, San Diego, USA 1997, 223-239.
• 24. Sudo J., Terui J., Higa T., Kikuta K., Yonekawa M., Kawamura A., Kon K., Kon T.: Futer accumulation of Cd in renal cellular membranes caused by administration of desferroxamine to Cd-burdened rats. Clin. Exp. Nephrol. 1999, 1, 23-28.
• 25. Taher A., Sheikh-Taha M., Koussa S., Inati A., Neeman R., Mourad F. H.: Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur. J. Hematol. 2001, 67, 30-34.
• 26. Voest E. E., Vreugdenhil G., Marx J. J. M.: Iron-chelating agents in non-iron overload conditions. Ann. Intern. Med. 1994, 120, 490-499.